Neurologia
Reumatologia
Gastroenterologia.net
Ematologia.net

Rheumatology.net

Rheumatology Xagena

Osteoarthritis is a leading cause of disability, characterized by the destruction of cartilage tissue in joints, but there is a lack of effective therapies because the underlying molecular causes have ...


Plasmacytoid dendritic cells have been implicated in the pathogenesis of systemic sclerosis through mechanisms beyond the previously suggested production of type I interferon.Researchers have isolated ...


Rheumatoid arthritis is a heterogeneous chronic disease, and no therapeutic agent has been identified which is universally and persistently effective in all patients. Researchers have investigated t ...


The 18-month efficacy of a single course of Rituximab ( MabThera, Rituxan ) as compared with conventional immunosuppression with Cyclophosphamide followed by Azathioprine in patients with severe ( org ...


Many patients with psoriasis develop psoriatic arthritis, a chronic inflammatory disease that afflicts peripheral synovial, axial, and entheseal structures. The fully human monoclonal antibody Ustekin ...


The vascular and gastrointestinal effects of non-steroidal anti-inflammatory drugs ( NSAIDs ), including selective COX-2 inhibitors ( coxibs ) and traditional non-steroidal anti-inflammatory drugs ( t ...


Orencia ( Abatacept ) SC ( subcutaneous ) and IV ( intravenous ) is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and im ...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product RoActemra ( To ...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product MabThera ( Rit ...


Eli Lilly has announced that it will discontinue the phase 3 rheumatoid arthritis ( RA ) program for Tabalumab, an anti-BAFF ( B cell activating factor ) monoclonal antibody, due to lack of efficacy. ...


the Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product Cimzia ( Certo ...


Dipeptidyl peptidase-4 inhibitors ( DPP4i ), such as Linagliptin, Saxagliptin, and Sitagliptin, are oral glucose-lowering drugs for type 2 diabetes mellitus ( T2DM ). DPP4 is a transmembrane glycoprot ...


Celgene has announced results of phase II trial ( BCT-001 ) on Apremilast, a oral targeted inhibitor of phosphodiesterase 4 ( PDE4 ), in patients with Behçet’s disease.These data have showed that sign ...


Celgene has announced results of its long-term phase III study on Apremilast, a targeted inhibitor of phosphodiesterase 4 ( PDE4 ), in systemic or biologic DMARD-naïve psoriatic arthritis patients.PAL ...


Eli Lilly and Incyte have announced 52-week efficacy and safety data from the open-label, long-term extension of the Phase 2b JADA study of Baricitinib in patients with active rheumatoid arthritis. Ba ...